Company Overview - Xeris is a fast-growing commercial biopharma company with three commercial products on the market [1] - The products include Gvoke for hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for hypercortisolemia and Cushing's syndrome [2] Product Portfolio - Gvoke is a rescue pen for hypoglycemia, similar to an EpiPen for diabetics [1] - Keveyis treats an ultra-rare hereditary genetic disorder known as primary periodic paralysis [2] - Recorlev is focused on hypercortisolemia and Cushing's syndrome, identified as a significant growth driver for the company [2] - The company is also developing XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism, which is ready for Phase III trials [2]